The Inflammatory Bowel Disease Treatment Market is expected to grow from US$ 24.05 billion in 2023 to US$ 31.67 billion by 2031; the market is anticipated to record a CAGR of 3.50% from 2023 to 2031.

Inflammatory bowel disease" (IBD) is a chronic inflammatory condition of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. These conditions cause inflammation of the digestive tract lining, leading to symptoms like abdominal pain, diarrhea, fatigue, and weight loss. Treatment aims to reduce inflammation, manage symptoms, and prevent complications through medication, lifestyle changes, and sometimes surgery. Managing IBD typically requires ongoing medical care and monitoring to maintain remission and improve quality of life.

Rising prevalence of Chron's Disease and Ulcerative Colitis

Crohn's disease, gastrointestinal disease due to trauma, bowel obstruction (BO), microscopic colitis, short bowel syndrome, and ulcerative colitis are a few of the common gastrointestinal diseases. According to an article published in Healthline in 2021, ~40% of people across the world were affected by functional gastrointestinal disorders. The Canadian Digestive Health Foundation states millions of Canadians live with digestive diseases; ~20 million Canadians, i.e., two of every three people, suffer from digestive disorders yearly. Enteral nutrition helps administer vital nutrients, which helps maintain strength, energy, and hydration levels in cancer patients (all stages).

Crohn's disease is a complex, chronic disorder primarily affecting the digestive system. The National Library of Medicine stated that there were 825 cases of IBD per 100,000 people in 2023, including compared to 410 cases of Crohn's disease and 414 cases of ulcerative colitis and IBD-u. With a prevalence of 0.82%, 322,600 Canadians were had IBD in 2023. Patients with gastrointestinal disease are at an increased risk of nutritional deterioration due to fasting requirements of diagnostic tests, therapeutic dietary restrictions, and loss of appetite due to anorexia or altered nutritional requirements caused by the disease itself. Thus, enteral nutrition is prescribed for gastrointestinal disease patients, as the enteral route is preferred to provide the required nutrients. Therefore, the rising prevalence of chron's disease and ulcerative colitis drives the growth of the Inflammatory Bowel Disease Treatment Market.

On the other hand, the high cost associated with treating inflammatory bowel disease (IBD) is indeed a significant barrier in the IBD treatment market. From expensive medications to frequent hospitalizations and surgeries, managing IBD can place a heavy financial burden on patients and healthcare systems alike. This cost factor often limits access to optimal care and innovative treatments for many individuals living with IBD. Addressing the affordability and accessibility of IBD treatments is crucial for improving outcomes and quality of life for patients affected by this chronic condition. Efforts to reduce costs and expand access to affordable therapies are essential in ensuring that individuals with IBD receive the care they need to manage their condition effectively. Thus, the high cost associated with treatment hinders the growth of the Inflammatory Bowel Disease Treatment Market.

The Inflammatory Bowel Disease Treatment Market analysis has been carried out by considering the following segments based on drug class, disease indication, and distribution channel. The market is classified into biologics, aminosalicyclates, corticosteroids, and others by drug class. The market is segmented into crohn's disease and ulcerative colitis based on disease indication. In the distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. The scope of the Inflammatory Bowel Disease Treatment Market report includes North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Based on geography, the Inflammatory Bowel Disease Treatment Market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America.

In 2023, North America held the largest Inflammatory Bowel Disease Treatment Market share. In North America, the US holds the largest market share in the world. Market growth in this country is attributed to the increase in the prevalence of inflammatory diseases, the presence of major market players, and their numerous strategic initiatives. Regional expansion is also being made easier by the region's improved payment rules, high treatment rates, and rising prescription of innovative medications. Developing innovative treatments through continuing research and encouraging government initiatives are also expected to fuel the region's expansion. For instance, some major groups, such as Crohn's & Colitis Foundation, are dedicated to promoting clinical and translational research to cure colitis and Crohn's disease.

Furthermore, Asia Pacific is expected to increase at the fastest rate. Some of the main reasons driving market expansion in the next years are the growing elderly population, associated with a higher chance of acquiring inflammatory disorders, the rising prevalence of inflammatory bowel diseases, and improvements in healthcare policy in the area. Furthermore, major players in the region are expected to increase their investments, and the growing use of biologics and biosimilars will likely fuel market growth in the near future.